Restoration of p53 function leads to tumour regression in vivo

@article{Ventura2007RestorationOP,
  title={Restoration of p53 function leads to tumour regression in vivo},
  author={A. Ventura and D. Kirsch and M. Mclaughlin and D. Tuveson and J. Grimm and L. Lintault and J. Newman and E. Reczek and R. Weissleder and T. Jacks},
  journal={Nature},
  year={2007},
  volume={445},
  pages={661-665}
}
  • A. Ventura, D. Kirsch, +7 authors T. Jacks
  • Published 2007
  • Biology, Medicine
  • Nature
  • Tumorigenesis is a multi-step process that requires activation of oncogenes and inactivation of tumour suppressor genes. Mouse models of human cancers have recently demonstrated that continuous expression of a dominantly acting oncogene (for example, Hras, Kras and Myc) is often required for tumour maintenance; this phenotype is referred to as oncogene addiction. This concept has received clinical validation by the development of active anticancer drugs that specifically inhibit the function of… CONTINUE READING
    1,467 Citations

    Figures and Topics from this paper.

    Explore Further: Topics Discussed in This Paper

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    This study is a Single-center, open, single-arm and non-randomized clinical trial in China. The aim of this study is to evaluate the efficacy, safety, and tolerability of Arsenic… Expand
    ConditionsEndometrial Cancer, Ovarian Cancer
    InterventionDrug
    Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy
    Pharmacological reactivation of p53 as a strategy to treat cancer
    • 54
    Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras
    • 52
    • PDF

    References

    SHOWING 1-10 OF 37 REFERENCES
    Essential role for oncogenic Ras in tumour maintenance
    • 859
    Temporal dissection of p53 function in vitro and in vivo
    • 176
    Tumor spectrum analysis in p53-mutant mice
    • 1,978
    Manipulation of the tumor suppressor p53 for potentiating cancer therapy.
    • 38